Earnings Performance - Kiniksa Pharmaceuticals reported a quarterly loss of $0 18 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0 01, representing an earnings surprise of -1,700% [1] - The company's loss per share improved from $0 20 a year ago, showing a year-over-year improvement [1] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Revenue Performance - Kiniksa Pharmaceuticals posted revenues of $112 21 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1 77% [2] - This represents a significant increase from year-ago revenues of $67 05 million [2] - The company has topped consensus revenue estimates four times over the last four quarters [2] Stock Performance - Kiniksa Pharmaceuticals shares have added about 57 3% since the beginning of the year, outperforming the S&P 500's gain of 22 1% [3] - The stock's immediate price movement will depend on management's commentary on the earnings call [3] Earnings Outlook - The current consensus EPS estimate is $0 02 on $119 26 million in revenues for the coming quarter and -$0 29 on $418 02 million in revenues for the current fiscal year [7] - The estimate revisions trend for Kiniksa Pharmaceuticals is favorable, translating into a Zacks Rank 2 (Buy) [6] Industry Context - Kiniksa Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry, which is currently in the top 30% of the 250 plus Zacks industries [8] - The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - Affimed N V, another stock from the same industry, is expected to post a quarterly loss of $1 14 per share, representing a year-over-year improvement of +32 9% [9] - Affimed N V's revenues are expected to be $1 41 million, down 34 4% from the year-ago quarter [9]

Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution – ARCALYST (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMYAward-winning singer-songwriter, Carly Pearce – – Kiniksa exp ...

Core Insights - Kiniksa Pharmaceuticals reported a significant increase in net product revenue for ARCALYST, reaching $112.2 million in Q3 2024, which represents a 73% year-over-year growth [1][6] - The company has raised its 2024 expected net product revenue for ARCALYST to between $410 million and $420 million, up from previous guidance [8] - Kiniksa is actively promoting disease awareness for recurrent pericarditis through the Life DisRPted campaign, collaborating with notable figures [3][2] Financial Performance - Total revenue for Q3 2024 was $112.2 million, compared to $67.0 million in Q3 2023 [6] - The net loss for Q3 2024 was $12.7 million, an improvement from a net loss of $13.9 million in Q3 2023 [7] - Total operating expenses for Q3 2024 were $121.9 million, up from $78.0 million in Q3 2023, with collaboration expenses increasing to $29.3 million [6][7] Product and Pipeline Updates - ARCALYST has been prescribed by over 2,550 prescribers since its launch in April 2021, with an average therapy duration of approximately 27 months for recurrent pericarditis [4] - Kiniksa is currently enrolling patients in a Phase 2b clinical trial for abiprubart, targeting Sjögren's Disease [5][2] Strategic Initiatives - The Life DisRPted campaign aims to enhance awareness and early diagnosis of recurrent pericarditis, featuring partnerships with Henrik Lundqvist and Carly Pearce [3] - Kiniksa expects to maintain annual cash flow positivity while continuing to invest in commercialization and pipeline advancement [2][8]

Core Insights - Kiniksa Pharmaceuticals International, plc will host a conference call and live webcast on October 29, 2024, at 8:30 a.m. Eastern Time to discuss its Q3 2024 financial results and recent portfolio execution [1] - The conference call will be accessible via the company's website, and participants can register to receive dial-in details [1] - A replay of the event will be available on Kiniksa's website approximately 48 hours after the call [1] Company Overview - Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with significant unmet medical needs [2] - The company's immune-modulating assets are based on strong biological rationale or validated mechanisms, targeting underserved cardiovascular and autoimmune conditions [2] - Kiniksa aims to offer differentiated therapeutic options in its market [2]

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock price trends for successful short-term investing, highlighting Kiniksa Pharmaceuticals, Ltd. (KNSA) as a strong candidate for trend investing due to its recent performance and positive fundamentals [1][3]. Group 1: Stock Performance - KNSA has experienced a solid price increase of 20.5% over the past 12 weeks, indicating strong investor interest and potential upside [4]. - The stock has also maintained a price increase of 4.1% over the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, KNSA is trading at 82.4% of its 52-week high-low range, indicating it may be on the verge of a breakout [5]. Group 2: Fundamental Strength - KNSA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like KNSA that are on an uptrend supported by strong fundamentals [3][8]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [8].

Kiniksa Pharmaceuticals, Ltd. (KNSA) closed the last trading session at $24.47, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.83 indicates a 42.3% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $3.92. While the lowest estimate of $30 indicates a 22.6% increase from the current price level, the most optimist ...

Core Viewpoint - The article emphasizes the importance of identifying and sustaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for maintaining momentum in stock prices [1]. Group 1: Stock Performance - Kiniksa Pharmaceuticals, Ltd. (KNSA) has shown a solid price increase of 41.2% over the past 12 weeks, indicating strong investor interest [3]. - The stock has maintained a price increase of 0.2% over the last four weeks, suggesting that the upward trend is still intact [4]. - KNSA is currently trading at 87.9% of its 52-week high-low range, indicating a potential breakout opportunity [4]. Group 2: Fundamental Strength - KNSA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [6]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like KNSA that are on an uptrend with strong fundamentals [2]. - There are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [7].

Core Viewpoint - Kiniksa Pharmaceuticals will participate in the 2024 Wells Fargo Healthcare Conference, indicating ongoing engagement with investors and the healthcare community [1]. Company Overview - Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing therapeutic medicines for patients with significant unmet medical needs [3]. - The company’s immune-modulating assets include ARCALYST®, abiprubart, and mavrilimumab, which target underserved cardiovascular and autoimmune conditions [3]. - Kiniksa aims to differentiate its products based on strong biological rationale and validated mechanisms [3]. Event Details - The fireside chat is scheduled for September 4, 2024, at 8:00 a.m. Eastern Time, showcasing the company's commitment to transparency and investor relations [1]. - A live webcast of the presentation will be available on Kiniksa's website, with a replay accessible within approximately 48 hours post-event [2].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to capitalize on established directions for profitable trades [1] Company Performance - Kiniksa Pharmaceuticals, Ltd. (KNSA) shares have increased by 33.69% over the past quarter and 39.98% over the last year, significantly outperforming the S&P 500, which moved 7.34% and 19.81% respectively [2] - KNSA's consensus earnings estimate improved from -$0.10 to -$0.05 over the past 60 days, with one upward revision and no downward revisions for the current fiscal year [3] Momentum Indicators - KNSA has a Momentum Score of B and is rated as a 1 (Strong Buy) stock, indicating strong potential for near-term gains [4][6] - The stock's short-term price activity shows a 0.09% increase over the past week, while the Zacks Medical - Biomedical and Genetics industry declined by 1.81% during the same period [9] - KNSA's monthly price change of 39.38% outperforms the industry's 5.35% performance [9] Trading Volume - KNSA's average 20-day trading volume is 684,469 shares, which serves as a bullish indicator when combined with rising stock prices [10] Estimate Revisions - The Zacks Momentum Style Score incorporates trends in estimate revisions, which have been positive for KNSA, indicating potential for continued performance [11]

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in short-term investing, highlighting Kiniksa Pharmaceuticals, Ltd. (KNSA) as a strong candidate for trend investing due to its recent price performance and fundamental strength [1][9]. Group 1: Price Performance - KNSA has experienced a solid price increase of 33.7% over the past 12 weeks, indicating strong investor interest [3]. - The stock is currently trading at 85.7% of its 52-week high-low range, suggesting it may be on the verge of a breakout [4]. - Over the past four weeks, KNSA's price has increased by 39.4%, confirming that the upward trend is still intact [10]. Group 2: Fundamental Strength - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [11]. - The stock also has an Average Broker Recommendation of 1 (Strong Buy), indicating high optimism from the brokerage community regarding its near-term price performance [12]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks like KNSA that have the fundamental strength to maintain their uptrend [2]. - The Zacks Rank stock-rating system has a proven track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988, suggesting that KNSA's price trend may continue positively [5].